After toiling for 40 years, ImmunoGen can now see the potential approval of its first wholly owned oncology drug on the horizon. The biotech is preparing to submit mirvetuximab soravtansine for approval after showing the antibody-drug conjugate (ADC) shrank ovarian tumors.
Investigators enrolled 106 patients with folate receptor alpha-high, platinum-resistant ovarian cancer who had received up to three prior lines of therapy to receive mirvetuximab. Half of the subjects had received three lines of therapy. All participants had previously received Avastin, and almost half had taken a PARP inhibitor.
